LEXINGTON, Mass. & SHANGHAI--(BUSINESS WIRE)--N-of-One, Inc., the global leader in clinical interpretation for precision medicine in oncology, and GenomiCare Biotechnology, a fast-growing precision medicine services company headquartered in Shanghai, China, today announced a signed agreement for N-of-One to provide clinical interpretation for GenomiCare’s comprehensive oncology panels. Financial terms of the agreement are not disclosed.
GenomiCare’s comprehensive oncology panel serves patients at leading hospitals across China. GenomiCare uses next-generation sequencing technology to identify mutations and copy number variations across the entire DNA exome of a patient’s tumor. By pairing this with a normal tissue sample from the same patient, GenomiCare can identify the unique, clinically-actionable genetic variations that are specific to each patient’s tumor—enabling the selection of the most appropriate drug therapies and creating a safer, more effective, and individualized approach to cancer therapy.
N-of-One Clinical Interpretation is based on proven, deep oncology domain expertise that is constantly updated by N-of-One’s in-house team of PhDs and oncologists. N-of-One delivers comprehensive scientific and clinical evidence that supports possible therapeutic strategies relevant to each specific patient case, including insights into the implications on drug sensitivity, drug resistance and potential combination therapies. N-of-One’s solution is configured to easily and efficiently integrate into each organization's reporting needs. N-of-One provides its clinical interpretation to world-leading cancer hospitals and diagnostics laboratories including the Mayo Clinic, Fox Chase Cancer Institute, CompanionDx, CellNetix and Intermountain Healthcare.
“Precision medicine with targeted therapy and immunotherapy has demonstrated significant clinical benefit in cancer care, and has already been incorporated into standard practice in most major US cancer centers and hospitals,” said Qiang Xu, president of GenomiCare. “We are excited to collaborate with N-of-One to bring the world’s leading clinical interpretation to China’s cancer doctors and patients. We believe the combination of this rich clinical knowledge, along with GenomiCare’s multiple avenues to connect patients with China-focused treatment solutions, will significantly benefit Chinese cancer patients.”
“N-of-One is very pleased to work with the talented team at GenomiCare,” said Chris Cournoyer, CEO of N-of-One. “We are focused on helping GenomiCare deliver valuable insights and evidence to clinicians in the large and fast growing China market.”
About GenomiCare Biotechnology
GenomiCare is a rapid growing private company headquartered in Shanghai, China, and with operations in Boston, US. Through a combined approach of genomics, medical informatics and enabling access to patient care, GenomiCare focuses on providing world-class clinical decision support services and precision medicine solutions that are uniquely tailored to the Chinese oncologist and patient communities. GenomiCare is a subsidiary of Carebridge Holdings, an integrated healthcare services company in China and the developer of Shanghai Jiahui International Hospital. For more information, please contact info@genomicarebio.com.
About N-of-One
N-of-One, the leader in clinical interpretation for oncology, leverages its world-class team of experts coupled with a proprietary delivery platform to deliver molecular decision support solutions and services, such as interpretation, to pathologists and oncologists at the point of care. N-of-One’s team of experts has interpreted thousands of samples for pathologists, oncologists and patients worldwide, through partnerships with leading diagnostic companies and hospital systems. N-of-One does not provide medical advice or promote any product or service. For more information, please visit www.n-of-one.com or call 617-202-9808.